Vitrakvi deemed ‘not cost-effective’ by NICE
The organisation, however, encourages further data collection on similar “game changing” histology independent cancer drugs.
Read More
Tag: neurotrophic tyrosine receptor kinase
- FDA approves new high dose Spinraza regimen for SMA
- Viridian reports positive results from elegrobart phase 3 trial
- Cure Parkinson’s convenes expert panel to assess £2 million combination therapy funding call
- Kygevvi approved in Europe as first treatment for TK2d
- Tozorakimab shows significant benefit in two major COPD trials
